Table 1 Population baseline characteristics
Characteristics | Values |
|---|---|
N | 48 |
Sex (male)—n (%) | 29 (60.4) |
Age (years)—mean (s.d.) | 65.4 (11) |
BMI (kg m−2)—mean (s.d.) | 28.3 (4.9) |
Pre-spironolactone BP—mean (s.d.) | |
Systolic BP, mm Hg | 156 (23) |
Diastolic BP, mm Hg | 87 (16) |
Comorbidities—n (%) | |
Diabetes | 16 (33.3) |
Hyperlipidemia | 1 (2.1) |
Ischemic heart disease | 11 (22.9) |
Cerebral vascular disease | 0 (0.0) |
Smoking | 3 (6.3) |
Antihypertensive drugs—median (s.d.) | 4.0 (1.0) |
Antihypertensive drugs, number—n (%) | |
2 | 6 (12.5) |
3 | 10 (20.8) |
4 | 25 (52.1) |
5 | 7 (14.6) |
Antihypertensive drugs, type—n (%) | |
Beta blocker | 40 (83.3) |
Calcium channel blocker | 41 (85.4) |
ACE inhibitor/AR blocker | 42 (87.5) |
Diuretic | 44 (91.7) |
Alpha blocker | 10 (20.8) |
Laboratory values—median (s.d.) | |
Sodium, mEq l−1 | 140 (3.35) |
Potassium, mEq l−1 | 4.3 (0.79) |
Creatinine, mg dl−1 | 1.08 (0.24) |
Urea, mg dl−1 | 40 (16.3) |
Target organ damage—n/tested (%) | |
Left ventricular hypertrophy | 19/27 (70.4) |
Microalbuminuria | 8/26 (30.8) |
